Rountree et al. prepared EVs with two tumor-associated antigens, prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP), by fusing them with the C1C2 domain of lactadherin [133]. The gene discussed is ACP3; the disease is neoplasm.